Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2682-2689

  Barrow, Esther L W ^a   Winchester, Gary A ^a   Staas, Jay K ^a   Quenelle, Debra C ^a   Barrow, William W ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID ETHYL ESTER; CARBOXYMETHYLCELLULOSE; DICHLOROMETHANE; MICROSPHERE; POLYGLACTIN; RIFAMPICIN;

ANIMAL CELL; ARTICLE; BIOASSAY; BIOCOMPATIBILITY; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

EID: 0031711748     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2682     Document Type: Article

References (42)

1. American, T. S. 1992. Control of tuberculosis in the United States. Am. Rev. Respir. Dis. 1992:1623-1633.
2. Amin, N. M. 1990. Let's stop the comeback of tuberculosis. Postgrad. Med. 88:107-124.
3. Barksdale, L., and K. S. Kim. 1977. Mycobacterium. Bacteriol. Rev. 41:217-372.
4. Bermudez, L. E. M., M. Wu, and L. S. Young. 1987. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin. J. Infect. Dis. 156:510-513.
5. Centers for Disease Control. 1990. Nosocomial transmission of multidrug-resistant tuberculosis to health-care workers and HIV-infected patients in an urban hospital. Florida. Morbid. Mortal. Weekly Rep. 39:718-722.
6. Centers for Disease Control. 1991. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons. Florida and New York. Morbid. Mortal. Weekly Rep. 40:649-652.
7. Cowsar, D. R., T. R. Tice, R. M. Gilley, and J. P. English. 1985. Poly(lactide-co-glycolide) microcapsules for controlled release of steroids. Methods Enzymol. 112:101-116.
8. Cynamon, M. H., C. E. Swenson, G. S. Palmer, and R. S. Ginsberg. 1989. Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. 33:1179-1183.
9. Deol, P., G. K. Khuller, and K. Joshi. 1997. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 41:1211-1214.
10. Duzgunes, N., V. K. Perumal, L. Kesavalu, J. A. Goldstein, R. J. Debs, and P. R. J. Gangadharam. 1988. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob. Agents Chemother. 32:1404-1411.
11. Edlin B. R., J. I. Tokars, M. H. Grieco, J. T. Crawford, J. Williams, E. M. Sordillo, K. R. Ong, J. O. Kilburn, S. W. Dooley, K. G. Castro, W. R. Jarvis, and S. D. Holmberg. 1992. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326:1514-1521.
12. Ehlers, S., W. Bucke, S. Leitzke, L. Fortmann, D. Smith, H. Hansch, H. Hahn, G. Bancroff, and R. Muller. 1996. Liposomal amikacin for treatment of M. avium infections in clinically relevant experimental settings. Zentralbl. Bakteriol. 284:218-231.
13. Eldridge, J. H., C. J. Hammond, J. A. Meulbroek, J. K. Staas, R. M. Gilley, and T. R. Tice. 1990. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release 11:205-214.
14. Eldridge, J. H., J. K. Staas, J. A. Meulbroek, T. R. Tice, and R. M. Gilley. 1991. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Intect. Immun. 59:2978-2986.
15. Fine, P. 1984. Leprosy and tuberculosis - an epidemiological comparison. Tubercle 65:137-153.
16. Gangadharam, P. R., D. R. Ashtekar, D. L. Flasher, and N. Duzgunes. 1995. Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes. Antimicrob. Agents Chemother. 39:725-730.
17. Gilding, D. K., and A. M. Reed. 1979. Biodegradable polymers for use in surgery polyglycolic/poly(lactic acid) homo- and copolymers. Polymer 20: 1459-1464.
18. Hora, M. S., R. K. Rana, J. H. Nunberg, T. R. Tice, R. M. Gilley, and M. E. Hudson. 1990. Release of human serum albumin from poly(lactide-co-glycolide) microspheres. Pharm. Res. 7:1190-1194.
19. Jacob, E., J. A. Setterstrom, D. E. Bach, J. R. Heath, L. M. McNiesh, and I. G. Cierny. 1991. Evaluation of biodegradable ampicillin anhydrate microcapsules for local treatment of experimental staphylococcal osteomyelitis. Clin. Orthop. Relat. Res. 267:237-244.
20. Leitzke, S., W. Bucke, K. Borner, R. Muller, H. Hahn, and S. Ehlers. 1998. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob. Agents Chemother. 42:459-461.
21. Morrow, P. E. 1974. Aerosol characterization and deposition. Am. Rev. Respir. Dis. 110:88-102.
22. National Action Plan To Combat Multidrug-Resistant Tuberculosis. 1992. Meeting the challenge of multidrug-resistant tuberculosis: summary of a conference. Management of persons exposed to multidrug-resistant tuberculosis. Morbid. Mortal. Weekly Rep. 41:1-71.
23. National Committee for Clinical Laboratory Standards. 1995. Antimycobacterial susceptibility testing for Mycobacterium tuberculosis: tentative standard. Report M24-T, vol. 15, no. 16. National Committee for Clinical Laboratory Standards, Villanova, Pa.
24. 23a. National Committee for Clinical Laboratory Standards. 1993. Document M2-A5, vol. 13, no. 24. National Committee for Clinical Laboratory Standards, Villanova, Pa.
25. Nightingale, S. D., S. L. Saletan, C. E. Swenson, A. J. Lawrence, D. A. Watson, F. G. Pilkiewicz, E. G. Silverman, and S. X. Cal. 1993. Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrob. Agents Chemother. 37:1869-1872.
26. Orozco, L. C., F. O. Quintana, R. M. Beltrán, I. de Moreno, M. Wasserman, and G. Rodriguez. 1986. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Tubercle 67:91-97.
27. Petersen, E. A., J. B. Grayson, E. M. Hersh, R. T. Dorr, S. M. Chiang, M. Oka, and R. T. Proffitt. 1996. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. J. Antimicrob. Chemother. 38:819-828.
28. Rastogi, N., M.-C. Potar, and H. L. David. 1987. Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J774: ultrastructure and drug-susceptibility studies. Curr. Microbiol. 16:79-92.
29. 6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc. Natl. Acad. Sci. USA 81:5845-5848.
30. Snider, D. E. J., M. Raviglione, and A. Kochi. 1994. Global burden of tuberculosis, p. 3-11. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C.
31. Tice, T. R., and D. R. Cowsar. 1984. Biodegradable eontrolled-release parenteral systems. J. Pharm. Technol. 8:26-36.
32. Tice, T. R., C. E. Rowe, R. M. Gilley, J. A. Setterstrom, and D. D. Mirth. 1986. Development of microencapsulated antibiotics for topical administration, p. 169-170. In Proceedings of the 13th International Symposium on Controlled Release of Bioactive Materials. Controlled Release Society, Inc., Lincolnshire, Ill.
33. United States Pharmacopeial Convention. 1990. U.S. Pharmacopeia, 22nd ed. U.S. Pharmacopeial Convention, Inc., Rockville, Md.
34. Visscher, G. E., R. L. Robison, and G. I. Argentieri. 1987. Tissue response to biodegradable injectable microcapsules. J. Biomater. Appl. 2:118-131.
35. Visscher, G. E., R. L. Robison, H. V. Maulding, J. W. Fong, J. E. Pearson, and G. I. Argentieri. 1985. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J. Biomed. Mater. Res. 19:349-365.
36. Visscher, G. E., R. L. Robison, H. V. Maulding, J. W. Fong, J. E. Pearson, and G. I. Argentieri. 1986. Biodegradation of and tissue reaction to microcapsules. J. Biomed. Mater. Res. 20:667-676.
37. Vladimirsky, M. A., and G. A. Ladigina. 1982. Antibacterial activity of liposome-entrapped streptomycin in mice infected with Mycobacterium tuberculosis. Biomedicine 36:375-377.
38. Wanger, A., and K. Mills. 1996. Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest. J.Clin. Microbiol. 34:1672-1676.
39. World Health Organization. 1993. WHO declares tuberculosis a global emergency. Soz-Praevmed. 38:251-52.
40. World Health Organization. 1994. TB: a global emergency. Report 94.177. World Health Organization, Geneva, Switzerland.
41. Wright, E. L., D. C. Quenelle, W. J. Suling, and W. W. Barrow. 1996. Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrob. Agents Chemother. 40:2206-2208.
42. Ziegler-Heitbrock, H. W. L., E. Thiel, A. Fütterer, V. Herzog, and A. Wirtz. 1988. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer 41:456-461.